Introduction
Over the past several years, a number of investigators have demonstrated the efficacy of angiogenic gene therapy for chronic myocardial ischemia in animal studies and in human trials. [1] [2] [3] [4] More recently, the concept of gene therapy-mediated growth factor treatment has been extended to the realm of acute myocardial ischemia. 5, 6 Possible benefits of angiogenic gene therapy in the setting of acute myocardial ischemia include a direct angiogenic effect, myocyte protection and protection of the integrity of the ventricular extracellular matrix. Myocyte protection may be conferred by the inhibition of apoptosis or other direct cell protective effects. 6, 7 Vascular endothelial growth factor (VEGF), one of the number of angiogenic growth factors, has been shown to preserve myocardial function in the setting of ischemia-reperfusion and to inhibit apoptosis in some systems. 8, 9 Furthermore, myocyte-secreted VEGF, acting via autocrine and paracrine pathways, has been shown to be critically important to the maintenance of normal ventricular structure and function. 10 It is thought that local decreases in myocyte-secreted tissue VEGF contribute to as yet unspecified mechanisms of ischemic heart failure, especially in diabetes. 11 We have demonstrated earlier the ability of TERPLEXmediated plasmid VEGF gene therapy to ameliorate the detrimental effects of coronary occlusion on left ventricular function and to promote functional recovery following myocardial infarction. 12 Unregulated expression, however, limits the efficacy and safety of VEGF gene therapy within the myocardium. [13] [14] [15] The potential for complications with constitutive gene expression and the reliance on the use of viral vectors have slowed the clinical application of gene therapy for patients with ischemic heart disease. To specifically address these issues, we have developed nonviral gene carriers, TERPLEX and water-soluble lipopolymer (WSLP), and an ischemia-inducible plasmid construct expressing VEGF, pRTP801-VEGF, to treat myocardial ischemia and infarction. 16 In this study, we compared the transfection efficiency of the polymer carriers in vitro, and then complexed the polymer carrier with the higher in vitro transfection efficiency to constitutive and ischemia-inducible VEGF gene constructs and compared their efficacy and mechanism of action in a series of in vivo models of myocardial ischemia and infarction.
Results
Representative myocardial (H9c2) and vascular (A7R5) cell types were transfected with various ratios of the polymer carriers, WSLP or TERPLEX, complexed to pRTP801-VEGF, to ascertain which polymer carrier demonstrated superior transfection efficiency under hypoxic conditions. WSLP transfection at a 10:1 N/P ratio produced as much VEGF as TERPLEX at its highest ratio (1:1:3 w/w) in H9c2 cells (Figures 1a and c) . VEGF expression in A7R5 cells was three times higher with the polymer carrier WSLP than that with the polymer carrier TERPLEX (Figures 1b and d) . VEGF levels following naked DNA transfection were uniformly non-significant in comparison with controls.
To determine whether VEGF expression affects viability and/or proliferation of myocardial and vascular cells, transfection of either cell type with the ischemiainducible expression plasmid, pRTP801-VEGF, complexed to WSLP at a 10:1 N/P ratio, was used and normalized to normoxic controls. Interestingly, the H9c2 cell line was not demonstrably affected by hypoxic conditions (Figure 2a ). Increased proliferation of H9c2 cells was exhibited over normoxic cells even with low VEGF expression, indicating these cells are quite responsive to small amounts of VEGF (Figures 1c and  2a) . However, any expression over a mean level of 30 pg ml À1 VEGF did not significantly change this proliferative capacity. This response was similar in A7R5 cells (Figures 1d and 2b) , except that A7R5 cells were appreciably affected by hypoxic conditions and the presence of VEGF prevented cell loss. These results indicate that WSLP was superior to TERPLEX in the transfection of cardiovascular cell lines, and therefore WSLP was the polymer selected for further in vivo studies.
An acute myocardial infarct model was used to demonstrate morphological and functional changes within the myocardium following treatment with either ischemia-inducible or constitutively expressed VEGF. After ligation of the left circumflex artery, animals were injected intramyocardially with either 200 mg of WSLP alone, 200 mg of WSLP/pSV-VEGF or 200 mg of WSLP/ pRTP801-VEGF complexes at three locations surrounding a defined ischemic border. Another group of control animals underwent left circumflex artery ligation alone. The early (o24 h) mortality was 14% and did not differ between groups. Twenty-two animals survived the immediate peri-operative period. Late mortality (424 h) occurred in the ligation only group (1/6, 16%) and did not differ between each of the four groups. There were five animals in each of the four study groups who survived over the length of the study. After 4 weeks treatment, hearts were excised and stained with triphenyltetrazolium.
Figures 3a-d contain representative photographs of the cross-sectioned left and right ventricles of the rabbit hearts at 4 weeks following circumflex artery ligation and injection therapy. Conversion of left ventricular muscle to infarcted fibrotic tissue appears whitish-pink, and the ratio of infarcted-to-non-infarcted left ventricle is demonstrated as follows: ligation only (no injection) ( Figure 3a) ; injection of WSLP alone ( Figure 3b) ; injection of WSLP/pSV-VEGF ( Figure 3c) ; and injection of WSLP/ pRTP801-VEGF (Figure 3d ).
Ligation alone resulted in the infarction of 48 ± 7% of the left ventricle (Figure 3a) . With injection of WSLP carrier alone, 49 ± 6% of the left ventricle was infarcted (P ¼ NS). The constitutively expressed gene construct, SV-VEGF, reduced infarct size to 32 ± 7% of the left ventricle (P ¼ 0.007). The ischemia-inducible gene construct, RTP801-VEGF, further reduced the infarct size to 13±4% of the left ventricle (Po0.001).
To compare differences in the mechanism of action of unregulated, constitutively expressed SV-VEGF and ischemia-inducible RTP801-VEGF, studies comparing the inhibition of apoptosis and the promotion of angiogenesis were performed. TUNEL staining was performed to compare inhibition of apoptosis, whereas CD141 staining was performed to compare the promotion of angiogenesis between the two forms of VEGF gene therapy. The WSLP/RTP801-VEGF group was able to restore the number of endothelial cells to levels comparable with the non-ligated controls at 43.6±1.8 per hpf (P ¼ NS). This is represented by the graph in Figure 5e . VEGF levels were measured by ELISA in the lungs, liver and plasma of rabbits 7 days after receiving RTP801-VEGF gene therapy and compared with control animals undergoing ligation only. There was no significant increase in VEGF levels in the lungs, liver or plasma of the rabbits receiving RTP801-VEGF gene therapy at 7 days compared with control, that is, ligation only rabbits (data not shown).
Having demonstrated the superior efficacy of the ischemia-inducible gene construct complexed to the WSLP carrier in vivo, we sought to confirm these results by repeating the injection of WSLP/RTP801-VEGF in an additional group of animals and comparing them with ligation only controls. The focus of these repeat experiments were the changes occurring along the endocardial surface, particularly the papillary muscles, with the injected gene therapy, as this would have the greatest clinical relevance. To allow a more complete analysis and comparison of the efficacy of the ischemia-inducible gene (Figures 6a and b) .
A standard assessment of the extent of remaining functional myocardium following infarction is left ventricular wall thickness. Using a precision vernal caliper, the mean wall thickness at the base of the papillary muscles for rabbits undergoing thoracotomy only (no ligation) was 5.5 ± 0.3 mm, whereas the mean wall thickness at the base of the papillary muscles in the ligation only group was 1.8 ± 0.4 mm (n ¼ 5 per group). In the WSLP/pRTP801-VEGF-treated groups, the left ventricular wall thickness was increased to 2.9 ± 0.2 mm, an increase in wall thickness of over 40% following infarction compared with the ligation only controls (Po0.01) ( Figure 7 ).
Discussion
We have previously shown that VEGF gene therapy can improve myocardial function and reduce left ventricular dilation following acute myocardial ischemia and infarction. 12 In this study, we systematically optimized gene delivery and compared the mechanism of action of ischemia-inducible with unregulated, constitutively expressed VEGF gene therapy. Although unregulated, constitutively expressed VEGF gene therapy reduced myocardial infarct size in this study, ischemia-inducible VEGF gene therapy demonstrated even greater efficacy. The mechanism for the improved efficacy seen with the ischemia-inducible VEGF gene therapy is as follows: (1) decreased apoptosis and (2) increased angiogenesis, compared with unregulated, constitutively expressed VEGF gene therapy following myocardial infarction. It is likely that both mechanisms contribute to the significant decrease in myocardial infarct size seen in this study. In addition to these two mechanisms, VEGF gene therapy has previously been shown to (1) promote arteriogenesis and (2) have a mitogenic effect on adult cardiomyocytes in large animal models of myocardial ischemia and infarction. [17] [18] [19] Both of these previously described mechanisms most likely also contribute to the significant decrease in myocardial infarct size seen in this study.
It is important to recognize that there are significant challenges in translating VEGF gene therapy into a viable clinical therapy to treat human patients with ischemic heart disease. One significant challenge is the heterogeneity in the biologic activity and response of VEGF across the patient populations presenting with ischemic heart disease. 20 VEGF expression in the myocardium is actually increased in diabetic patients with preserved ventricular function, whereas the expression of VEGF receptors and subsequent signal transduction is decreased. 21 As diabetic patients with ischemic cardiomyopathy develop progressive congestive heart failure, however, local myocyte-secreted tissue VEGF levels begin to fall, further exacerbating the declining ventricular function seen in these patients.
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In our rabbit model, with ligation of the proximal circumflex coronary artery, an infarction of the lateral wall of the left ventricle is produced. On the endocardial surface of the heart, this infarction is reliably centered at the base of the papillary muscles. With transmural infarction, the myocytes at the base of the papillary muscles are replaced by collagen. As a result, following ligation of the circumflex coronary artery with transmural infarction, there is a reproducible decrease in the wall thickness of the heart at the base of the papillary muscles. The increase in wall thickness seen in the WSLP/pRTP801-VEGF treated-groups provides additional evidence that WSLP/pRTP801-VEGF helps to preserve viable myocardium, a potentially important mechanism to decrease the deleterious effects of remodeling, which are commonly seen clinically following myocardial infarction.
Prior clinical trials with VEGF used plasmids that did not incorporate the regulatory elements of the VEGF gene. In vivo, the expression of VEGF is normally controlled by its own hypoxia-driven regulatory system at two different levels: transcription and translation. The VEGF promoter has a hypoxia-responsive element that binds to the hypoxia-inducible factor-1a and activates the transcription of the gene under conditions of hypoxia. [22] [23] [24] After transcription, VEGF mRNA is stabilized by the cooperation of multiple RNA elements, such as coding regions and 5 0 -and 3 0 -untranslated regions, resulting in an increase of the translation rate. [25] [26] [27] Excessive gene expression can be associated with severe side effects. Overexpression of VEGF can lead to several important problems, including the formation of vascular tumors, or angiomas. 15 This is of particular concern within the heart, as angiomas constitute spaceoccupying lesions that lead to heart failure and death. 14 Another problem is that unregulated, normoxic VEGF activity has been shown to promote the progression of atherosclerotic lesions, a significant concern in treating patients with ischemic heart disease. 13 Finally, the systemic expression of VEGF could potentially exacerbate diabetic retinopathy or promote angiogenesis of peripheral tumors. 28 These problems suggest that for gene therapy to become acceptably safe and widely applicable, regulation of the expression of the gene product will become essential.
To alleviate these inherent detriments, we have utilized a unique ischemia-inducible promoter (RTP801) to replicate the physiologic control of the VEGF gene, which is found in vivo. 16 This RTP801 promoter regulates VEGF expression in response to tissue ischemia at the transcription, translation and post-translation levels using an ischemia-inducible promoter. Once the RTP801-VEGF gene therapy-directed angiogenesis has restored normal tissue oxygen tension, no significant additional protein is expressed. Peripheral gene expression is negligible, as normal tissue oxygen tension at distant sites does not induce the expression of the angiogenic peptide. These temporal and regional controls of gene expression expand the safety profile for gene therapy-mediated angiogenesis within the target organ.
The construction of a plasmid, which is more responsive to the pathophysiology likely to be encounIschemia-inducible gene therapy JW Yockman et al tered in vivo, is only one aspect of the development of therapeutic genes for the treatment of myocardial ischemia and its complications. The lack of an optimal gene carrier also severely hinders the clinical application of gene therapy as a method of treatment for disease. 29 Advances in genetic engineering, chemical synthesis techniques and molecular biology have worked synergistically with increasing knowledge of the pathophysiology of the cardiovascular system to spur the development of synthetic, non-viral gene delivery systems for the treatment of ischemic heart disease.
Cationic polymers are ideal for use as gene carriers because they can be designed and synthesized to have specific properties. 29 These transfection systems have benefits over viral carriers in that DNA size is less restricted and there is minimal immunogenicity and toxicity. 6, 30, 31 All of these viral vectors have the potential for the regeneration of wild-type, replication-competent strains and have, at some point, been associated with or caused death. [32] [33] [34] [35] These risks are especially problematic in patients with ischemic cardiomyopathy who may ultimately need a cardiac transplant and will require chronic immunosuppression. 36, 37 In addition, non-viral carriers have an opportunity to optimize and modify these transfection systems to appropriately target therapy to the unique properties of the target tissue. 38, 39 These polymer gene carriers are nontoxic and do not integrate into the host genome, avoiding many of the risks of viral vector-mediated gene therapy. Although the spectrum of materials and methods has increased in recent years, polyethylenimine (PEI) remains the standard by which most nonviral gene carriers are compared. 
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The molecular weight of PEI plays a significant role in transfection efficiency and toxicity. 40 Lower molecular weights of PEI exhibit poor transfection characteristics with virtually no toxicity. As the molecular weight of PEI increases, transfection efficiency increases, as well as cytotoxicity. The reduced transfection efficiency of PEI (1.8 kDa) is attributed to its dissociative properties in physiological salt concentrations. Amine groups providing the charge for condensation also allow for the conjugation of targeting moieties and shielding agents to overcome extracellular and intracellular obstacles plagued by polycationic gene delivery. Several cholesterol-based cationic lipids have been generated as gene carriers and have demonstrated high transfection efficiency in mammalian cells, but most lacked an effective endosomal escape mechanism such as found in PEI. 
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To overcome these limitations, we have developed a novel WSLP gene carrier with multifunctional capabilities. 44, 45 The WSLP gene carrier forms self-assembling lipopolymer/DNA complexes with the therapeutic gene. The multifunctional characteristics of these novel polymers include DNA condensation, protection of DNA integrity, cell membrane adhesion and endosomal disruption capabilities with minimal toxicity. The use of this polymer has been used to deliver genes to several different cancers, myocardium and corpus cavernosum. [45] [46] [47] [48] [49] In summary, we have demonstrated that ischemiainducible VEGF gene therapy improves the efficacy of VEGF gene therapy for myocardial infarction through decreased apoptosis and increased angiogenesis.
Methods
Plasmid preparation
Plasmid carrying the VEGF-165 coding region under the control of the Simian virus 40 (SV40) immediateearly promoter enhancer region and the chicken bglobulin intron (pSV-VEGF) were created. The therapeutic gene was inserted into pSI (Promega, Madison, WI, USA) on the basis of the MluI and BamHI restriction sites.
The pRTP801-VEGF plasmid was generated by cloning the RTP801 promoter into the SV-VEGF plasmid as described earlier. 16 Briefly, the SV40 promoter was eliminated from the SV-VEGF plasmid by digestion with BglII and HindIII, and the plasmid backbone was purified by gel electrophoresis. The RTP801 promoter was synthesized using primers described earlier, digested and inserted into the backbone plasmid to regulate the expression of VEGF in response to tissue ischemia.
Polymer synthesis
WSLP and TERPLEX were synthesized as described earlier. 12, 44, 45 In vitro analysis H9c2 and A7R5 cells were grown in 24-well plates with 500 ml complete media (DMEM+10% FBS). At 50% In vitro viability under hypoxia was accomplished by transfecting H9c2 or A7R5 cells with 1 mg of WSLP/ pRTP801-VEGF at similar N/P ratios as described above. Once the medium was changed 4 h later, the cells were placed in a hypoxia chamber with a mixture consisting of 1% O 2 , 94% N 2 , and 5% CO 2 . Supernatant was removed from the wells 48 h later and assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) to assess viability. This viability was normalized to normoxic cells over the same time period.
In vivo animal model
All experiments were approved by the University of Utah Institutional Animal Care and Use Committee and followed the guidelines provided by the National Institutes of Health in Guide for the Care and Use of Laboratory Animals.
New Zealand white rabbits (Western Oregon, Philomath, OR, USA), weighing 2.5-3.5 kg, were sedated with ketamine (50 mg kg
À1
, intramuscularly) and xylazine (8.8 mg kg
, intramuscularly), shaved and endotracheally intubated. The left chest was sterilely prepped and draped, and a surgical plane of anesthesia was obtained with isoflurane. Animals were maintained on a rodent ventilator (Harvard Apparatus, Cambridge, MA, USA) with a respiratory rate of 60 and 40% FiO 2 . Twenty rabbits underwent ligation of the proximal circumflex coronary artery. A left thoracotomy was performed through the third intercostal space, the lung was retracted and the pericardium was widely opened. A 5-0 Prolene suture was placed around the proximal circumflex artery and a 10-s test occlusion was performed to determine the area of the ventricle at risk. Five rabbits underwent thoracotomy or ligation only and served as the control groups. Immediately following ligation, three additional groups of rabbits underwent the injection of one of the following: (a) WSLP/pRTP801-VEGF complexes (10:1 N/P); (b) WSLP/pSV-VEGF (10:1 N/P); or (c) WSLP only (200 mg), (n ¼ 5 per group). Three injections totaling 200 mg of WSLP with or without plasmid in a total of 750 ml of solution were placed intramyocardially with a 30-gauge needle at the border zone surrounding the area at risk for each of the groups. Rabbits were weaned from anesthesia and extubated when breathing spontaneously. Postoperative pain was controlled with buprenorphine (0.05 mg kg
, intramuscularly) every 12 h for 48 h. The rabbits were killed at 4 weeks after sedation with ketamine, and the ratio of infarcted to non-infarcted left ventricular area was measured and expressed as the percentage of the left ventricle infarcted. Animals were randomly assigned to each of the four groups and the operating surgeon was blinded to each of the groups.
Infarct size analysis
For the measurement of transmural infarct size, myocardial tissue was placed in a clear food wrap and put in a À20 1C freezer for 1-2 h. Once the tissue was solid, it was cut into B3-mm-thick slices. A two-part buffer system consisting of low pH NaH 2 PO 4 (0.1 M) and high pH Na 2 HPO 4 (0.1 M) was mixed to achieve a pH of 7.4. A total of 400 mg of triphenyltetrazolium salt at 1% (w/v) (1 g/100 ml) was added to 40 ml of buffer. The slices were then incubated in the tetrazolium stain at a temperature of 37 1C. The heart slices were continuously agitated to keep the slices from touching the bottom or sides of the beaker for 15-20 min. Once the color was established, the slice was fixed in 10% formalin for B20 min. With this method, living tissue reliably turns a deep red color, whereas infarcted tissue reliably turns a whitish-pink color. The area of normal and infarcted left ventricular myocardium was measured using standard planimetry software (NIH ImageJ). The percentage of infarcted left ventricular myocardium was calculated by dividing the total area of infarcted myocardium (all sections) by the total area of the left ventricle and multiplying by 100.
For the measurement of endocardial infarct size, myocardial tissue was excised and placed in a solution of 10% formalin and saturated in picric acid for 48 h. Samples were then washed in tap water for 2 h twice to remove the picric acid. The endocardial aspect of the picric acid-stained left ventricular myocardium was photographically acquired as a standard 24-bit RGB digital image. The zero-delimited difference between the blue and green channels was offset by a value chosen to retain the image's dynamic range and then rendered as a grayscale image using the Calculations functionality of Photoshop CS2. All images were captured at a predetermined fixed focal length and focal distance such that a full-width 4368 pixel image captured a focal field width of 86 mm. This permitted conversion of the resulting scar tissue area in pixels, A pxl , to an affected area in mm 2 , A mm 2 , using the conversion A mm 2 ¼ (86 mm) 2 Â A pxl /(4368 pixels) 2 . All remaining processing was performed with NIH ImageJ. Contrast was enhanced and brightness adjusted with parameters Ischemia-inducible gene therapy JW Yockman et al recorded. Areas of the image not relevant to the analysis were bounded out and blackened. Thresholding was performed to yield a binary image of black scar tissue on white background. Outlining of the black (scar) areas was performed, and the 'Analyze Particles' function was used to quantitate the pixels inside the outline.
Wall thickness was measured using a Marathon electronic digital micrometer (Marathon Watch Co., Marathon, Ontario, Canada) at the base of the papillary muscles of the left ventricle. The micrometer was adjusted so that the myocardial wall was immobile between the micrometer poles but negligibly compressed or distorted.
Endothelial Cell Staining with CD141
Formalin-fixed paraffin-embedded tissue samples from the border zone of the infarction were cut at 3-4 mm on positively charged slides (Surgipath Medical Industries Inc., Richmond, IL, USA). The slides were allowed to air dry and then placed in a 60 1C oven for 30 min. Heatinduced epitope retrieval was performed in citrate buffer at pH 6.0 in an electric pressure cooker for 4 min. Slides were rinsed in dH 2 O. Antibody to CD141 (AbD Serotec, Raleigh, NC, USA) was applied undiluted onto slides and incubated overnight at room temperature. Detection of slides was performed on the Ventana ES automated system using the iView DAB detection kit (Ventana Medical Systems Inc., Tucson, AZ, USA). Slides were counterstained with hematoxylin for 4 min and then removed from the autostainer and placed in a mixture of DAWN/dH 2 O. Slides were washed in the DAWN/dH 2 O to remove any oil applied by the autostainer and then placed in iodine to remove any precipitate from fixation. Slides were placed in sodium thiosulfate to clear iodine and then rinsed in dH 2 O. Slides were de-hydrated in graded alcohols (70% Â 1, 95% Â 2 and 100% Â 2) for 30 s each and then cleared in four changes of xylene 10 dips each. The specimens were then examined over a total of five high-power fields (hpf) per specimen. The value assigned to each specimen was the mean of these five measurements (n ¼ 5 per group).
TUNEL staining for apoptosis
Terminal deoxynucleotidyl transferase (Tdt)-mediated dUDP nick-end labeling (TUNEL) for the detection of apoptosis was performed by following the manufacturer's directions of a ApopTag Plus Peroxidase In Situ Apoptosis kit (Intergen Company, Purchase, NY, USA) on myocardium. The tissue from the border zone of the infarction was then examined over a total of five hpf per specimen. The value assigned to each specimen was the mean of these five measurements (n ¼ 5 per group).
Adjacent organ VEGF levels
To assess the presence of VEGF in adjacent organs following injection therapy into the myocardium, VEGF levels in the lung, liver and serum were measured 4 days after myocardial infarction in rabbits receiving injection therapy with WSLP/pRTP801-VEGF and rabbits receiving no injection therapy. hVEGF levels were measured using the Chemikine VEGF Sandwich ELISA (Chemicon, Billerica, MA, USA).
Statistical methods
Differences between groups were assessed using Prism 4.0 software (Graphpad Software Inc., San Diego, CA, USA). Unpaired t-tests were used to compare unpaired continuous variables and paired t-tests were used for paired continuous variables. One-way analysis of variance was used when comparing three or more groups. Results are reported as the mean ± s.d. Po0.05 was considered statistically significant.
